Day: March 20, 2025

Fortified Balance Sheet of $113.0 Million Enables Company to continue R&D activities in AI-Driven Customer Platform in other Corporate Initiatives 2024 Annual Meeting of Stockholders Scheduled for May 6, 2025 AUSTIN, Texas, March 20, 2025 (GLOBE NEWSWIRE) — Phunware, Inc. (“Phunware” or the “Company”) (NASDAQ: PHUN), a leader in enterprise cloud solutions for mobile applications, today reported financial results for the year ended December 31, 2024. Financial HighlightsFor the year ended December 31, 2024, net loss from continuing operations was $10.3 million, as compared to $41.9 million in the previous period, while adjusted EBITDA loss improved to $10.3 million for the year ended December 31, 2024, compared to $15.5 million in the previous year period. Net cash used in operations was $13.3 million for the year ended December...

CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, March 20, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced its financial results for the year ended December 31, 2024, and reported on recent and upcoming business highlights. Martin Lehr, CEO of Context, commented, “We believe 2024 was a transformative year for Context, marked by strategic acquisitions, a strengthened financial position, and enhancements to our leadership team, all aligning with our mission to develop innovative T cell-engaging bispecific...

Geneva, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) — Schedules Conference Call and Webcast for Monday, March 24 at 10:00 am ET (3:00 pm CET)Ends the year with a strong cash position of approximately $85 million FY 2024 $11 million revenue reflects the industry-wide transition from traditional semiconductors to next-generation Quantum Resistant chips Expects a return to growth in FY 2025 Continues R&D investments with $7.2 million allocated in 2025, up from $5 million in 2024 Confirmed bookings of $6.8 million as of March 20, 2025, reflecting strong YoY growth $93 million in projected contract pipeline over next three years from 2026 to 2028 Executing a multi-faceted organic growth, investment and acquisition strategySEALSQ Corp (NASDAQ: LAES) (“SEALSQ” or “Company”), a company that focuses...

Motorsport Games Reports Fourth Quarter & Full Year 2024 Financial ResultsMotorsport Games Reports Fourth Quarter & Full Year 2024 Financial ResultsMIAMI, March 20, 2025 (GLOBE NEWSWIRE) — Motorsport Games Inc. (NASDAQ: MSGM) (“Motorsport Games” or “the Company”) today reported financial results for its fourth quarter and fiscal year ended December 31, 2024. The Company has also posted the fourth quarter and fiscal year-end 2024 earnings slides highlighting key milestones that occurred during and subsequent to the period, which are accessible on the Company’s investor relations website. “2024 was a revitalizing year for the company with improved revenues, reduced cash burn and the release of our new title Le Mans Ultimate in Early Access,” commented Stephen Hood, President and Chief Executive Officer of Motorsport...

Delivered Total and Net Investment Income of $33.8 million and $14.6 million, Respectively Investment Portfolio of $1.1 billion Conference Call Today, Thursday, March 20, 2025 at 5:00 p.m. ET MENLO PARK, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Runway Growth Finance Corp. (Nasdaq: RWAY) (“Runway Growth” or the “Company”), a leading provider of flexible capital solutions to late- and growth-stage companies seeking an alternative to raising equity, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2024. Fourth Quarter 2024 HighlightsTotal investment income of $33.8 million Net investment income of $14.6 million, or $0.39 per share Net asset value of $514.9 million, or $13.79 per share Dollar-weighted annualized yield on debt investments of 14.7% for the quarter Two investments completed...

– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and ABI-1179, long-acting helicase-primase inhibitor candidates for recurrent genital herpes – SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) — Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today reported financial results for the year ended December 31, 2024, and recent highlights. “We are well-positioned to deliver important clinical data on four of our novel antiviral candidates in 2025, including proof-of-concept efficacy data expected this fall from the Phase 1b studies of ABI-5366...

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) — LPL Financial LLC (“LPL Financial”), a wholly owned subsidiary of LPL Financial Holdings Inc. (Nasdaq: LPLA) (the “Company”), today released its monthly activity report for February 2025. Total advisory and brokerage assets at the end of February were $1.82 trillion, an increase of $11.3 billion, or 0.6%, compared to the end of January 2025. Total net new assets for February were $24.5 billion, which included $0.7 billion of acquired net new assets. Total organic net new assets for February were $23.8 billion, translating to a 15.8% annualized growth rate. This included $13.7 billion of assets from Prudential Advisors (“Prudential”) and $0.3 billion of assets from Wintrust Investments, LLC and certain private client business at Great Lakes Advisors, LLC (collectively, “Wintrust”) that...

MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent HighlightsDelivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023; Increased demand for OviTex® and OviTex PRS Reinforced Tissue Matrix products during the full year 2024, resulting in growth in unit sales volume for each product of approximately 33% and 31%, respectively; Drove expanded adoption of Company products in hernia procedures with the launch of OviTex IHR Reinforced Tissue Matrix, specifically...